
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion AS has demonstrated significant advancements in its clinical-stage oncology pipeline with an impressive 81% prediction accuracy of immunogenic neoantigens as reported in the revised PIONEER AI model data, indicating consistent improvement in predictive capabilities. The company achieved a promising overall response rate (ORR) of 75% for its EVX-01 therapy in combination with pembrolizumab, surpassing previous efficacy metrics and comparing favorably to competitor data. Additionally, the high percentage of patients experiencing deepened responses and sustained effectiveness at the 24-month mark highlights the robustness of Evaxion's innovative approach to personalized vaccines, reinforcing its leadership position in the neoantigen cancer vaccine sector.
Bears say
Evaxion AS faced negative market reactions to its stock, despite a strong data update regarding its product EVX-01, primarily due to the lack of clear expectations regarding the product's contribution to overall commercial viability. The company's reliance on AI-driven immunotherapy models appears to be met with skepticism from investors, reflected in the stock's underperformance. Furthermore, the contrasting sentiment highlights an ongoing struggle to translate clinical advancements into tangible financial growth, contributing to a cautious outlook on the company's future.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares